Palisade Bio (PALI) Times Interest Earned (2010 - 2026)
Palisade Bio (PALI) reported Times Interest Earned of -$10748.0 for Q1 2026, down 365.28% year-over-year from $4051.5 in Q1 2025, and down 115.37% on a QoQ basis from -$4990.5 in Q4 2025.
Palisade Bio (PALI) has 17 years of Times Interest Earned data on file, last reported at -$10748.0 in Q1 2026.
- Quarterly Times Interest Earned fell 365.28% year-over-year to -$10748.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2649.4 (down 135.57% YoY) and the FY2025 annual result came in at -$1805.6, down 45.82% from the prior year.
- Times Interest Earned slipped to -$10748.0 in Q1 2026 per PALI's latest filing, from -$4990.5 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$472.25 in Q3 2023 and bottomed at -$10748.0 in Q1 2026.
- The 5-year median for Times Interest Earned is -$1242.8 (2022), against an average of -$2313.2.
- The widest annual swing landed in 2022, when Times Interest Earned sank 340348.72%; it then surged 57.19% in 2023.
- Tracing PALI's Times Interest Earned over 5 years: stood at -$1282.7 in 2022, then jumped by 38.53% to -$788.5 in 2023, then plunged by 42.97% to -$1127.3 in 2024, then sank by 342.68% to -$4990.5 in 2025, then sank by 115.37% to -$10748.0 in 2026.
- Per Business Quant, the three latest PALI Times Interest Earned figures stand at -$10748.0 (Q1 2026), -$4990.5 (Q4 2025), and -$584.4 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | -10,748.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10,748.00 |
| Dec 31, 2025 | -4,990.50 |
| Sep 30, 2025 | -584.40 |
| Jun 30, 2025 | -1,421.50 |
| Mar 31, 2025 | -2,310.00 |
| Dec 31, 2024 | -1,127.33 |
| Sep 30, 2024 | -598.83 |
| Jun 30, 2024 | -2,105.50 |
| Mar 31, 2024 | -3,673.00 |
| Dec 31, 2023 | -788.50 |
| Sep 30, 2023 | -472.25 |
| Jun 30, 2023 | -1,203.00 |
| Dec 31, 2022 | -1,282.67 |
| Sep 30, 2022 | -1,103.25 |
| Jun 30, 2022 | -714.40 |
| Mar 31, 2022 | -3,888.00 |
| Dec 31, 2021 | -805.40 |
| Sep 30, 2021 | -116.00 |
| Jun 30, 2021 | -50.16 |
| Mar 31, 2021 | -1.14 |
| Dec 31, 2020 | -16.56 |
| Sep 30, 2020 | -64.86 |
| Jun 30, 2020 | -218.62 |
| Mar 31, 2020 | -771.80 |
| Dec 31, 2019 | -475.70 |
| Sep 30, 2019 | -1,110.39 |
| Jun 30, 2019 | -3,783.79 |
| Mar 31, 2019 | -1,217.93 |
| Dec 31, 2018 | -514.49 |
| Sep 30, 2018 | -1,390.30 |
| Jun 30, 2018 | -2,620.43 |
| Mar 31, 2018 | -1,223.43 |
| Dec 31, 2017 | -704.00 |
| Sep 30, 2017 | -1,871.20 |
| Jun 30, 2017 | -268.20 |
| Mar 31, 2017 | -30.50 |
| Dec 31, 2016 | -29.45 |
| Sep 30, 2016 | -20.45 |
| Jun 30, 2016 | -11.89 |
| Mar 31, 2016 | -16.13 |
| Dec 31, 2015 | -9.91 |
| Sep 30, 2015 | -11.20 |
| Jun 30, 2015 | -10.88 |
| Mar 31, 2015 | -10.17 |
| Dec 31, 2014 | -10.82 |
| Sep 30, 2014 | -11.36 |
| Jun 30, 2014 | -8.83 |
| Mar 31, 2014 | -11.96 |
| Dec 31, 2013 | -6.03 |
| Sep 30, 2013 | -8.09 |
| Jun 30, 2013 | -7.37 |
| Mar 31, 2013 | -59.92 |
| Dec 31, 2012 | -2,996.51 |
| Sep 30, 2012 | -7,710.92 |
| Jun 30, 2012 | -3,965.48 |
| Mar 31, 2012 | -2,887.71 |
| Dec 31, 2011 | -3,120.62 |
| Dec 31, 2010 | 1.81 |
| Sep 30, 2010 | -8,437.95 |
| Jun 30, 2010 | -2,869.42 |